Abstract
Background: Doping with growth hormone (GH) is banned; however, there is anecdotal evidence that it is widely abused. GH is reportedly often used in combination with anabolic steroids at high doses for several months. Development of a robust test for detecting GH has been challenging since recombinant human 22-kDa GH used in doping is indistinguishable analytically from endogenous GH and there are wide physiological fluctuations in circulating GH concentrations. Discussion: One approach to GH testing is based on measurement of different circulating GH isoforms using immunoassays that differentiate between 22-kDa and other GH isoforms. Administration of 22-kDa GH results in a change in its abundance relative to other endogenous pituitary GH isoforms. The differential isoform method is, however, limited by its short time window of detection. A second approach that extends the time window of detection is based on detection of increased levels of circulating GH-responsive proteins, such as the insulin-like growth factor (IGF) axis and collagen peptides. As age and gender are the major determinants of variability for IGF-I and the collagen markers, a test based on these markers must take these factors into account. Extensive data now validate the GH-responsive marker approach, and implementation is largely dependent on establishing an assured supply of standardized assays. Conclusions: Robust tests are available to detect GH and enforce the ban on its abuse in sports. Novel approaches that include gene expression and proteomic profiling must continue to be pursued to expand the repertoire of testing approaches available and to maintain deterrence of GH doping.
Journal Section:
Adult Workshop 1
References
1.
Nelson AE, Ho KK: Abuse of growth hormone by athletes. Nat Clin Pract Endocrinol Metab 2007;3:198–199.
2.
Bamberger M, Yaeger D: Over the edge: special report. Sports Illustrated 1997;86:64.
3.
Rickert VI, Pawlak-Morello C, Sheppard V, Jay MS: Human growth hormone: a new substance of abuse among adolescents? Clin Pediatr (Phila) 1992;31:723–726.
4.
Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE: Monitoring the Future National Survey Results on Drug Use, 1975–2006: Volume I, Secondary School Students. Bethesda, National Institute on Drug Abuse, 2007, NIH Publication No. 07-6205.
5.
NCAA: NCAA Study of Substance Use of College Student-Athletes. Indianapolis, NCAA, 2006.
6.
Saugy M, Robinson N, Saudan C, Baume N, Avois L, Mangin P: Human growth hormone doping in sport. Br J Sports Med 2006;40(suppl 1):i35–i39.
7.
Parkinson AB, Evans NA: Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc 2006;38:644–651.
[PubMed]
8.
Woodhouse LJ, Mukherjee A, Shalet SM, Ezzat S: The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr Rev 2006;27:287–317.
[PubMed]
9.
Healy ML, Gibney J, Russell-Jones DL, Pentecost C, Croos P, Sönksen PH, Umpleby AM: High dose growth hormone exerts an anabolic effect at rest and during exercise in endurance-trained athletes. J Clin Endocrinol Metab 2003;88:5221–5226.
[PubMed]
10.
Liu H, Bravata DM, Olkin I, Friedlander A, Liu V, Roberts B, Bendavid E, Saynina O, Salpeter SR, Garber AM, Hoffman AR: Systematic review: the effects of growth hormone on athletic performance. Ann Intern Med 2008;148:747–758.
11.
Weissberger AJ, Ho KY, Stuart MC: Quantification of urinary growth hormone (GH) excretion by centrifugal ultrafiltration and radioimmunoassay: appraisal of the relationship between 24 h urinary GH and mean 24 h serum GH levels in normal and abnormal states of GH secretion. Clin Endocrinol (Oxf) 1989;30:687–698.
12.
Flanagan DE, Taylor MC, Parfitt V, Mardell R, Wood PJ, Leatherdale BA: Urinary growth hormone following exercise to assess growth hormone production in adults. Clin Endocrinol (Oxf) 1997;46:425–429.
13.
Saugy M, Cardis C, Schweizer C, Veuthey JL, Rivier L: Detection of human growth hormone doping in urine: out of competition tests are necessary. J Chromatogr B Biomed Appl 1996;687:201–211.
14.
Kazlauskas R, Howe C, Trout G: Strategies for rhEPO detection in sport. Clin J Sport Med 2002;12:229–235.
15.
Holl RW, Schwarz U, Schauwecker P, Benz R, Veldhuis JD, Heinze E: Diurnal variation in the elimination rate of human growth hormone (GH): the half-life of serum GH is prolonged in the evening, and affected by the source of the hormone, as well as by body size and serum estradiol. J Clin Endocrinol Metab 1993;77:216–220.
[PubMed]
16.
Leung KC, Howe C, Gui LY, Trout G, Veldhuis JD, Ho KK: Physiological and pharmacological regulation of 20-kDa growth hormone. Am J Physiol Endocrinol Metab 2002;283:E836–E843.
[PubMed]
17.
Giustina A, Veldhuis JD: Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998;19:717–797.
[PubMed]
18.
Gibney J, Healy ML, Sönksen PH: The growth hormone/insulin-like growth factor-I axis in exercise and sport. Endocr Rev 2007;28:603–624.
19.
Baumann G: Growth hormone heterogeneity in human pituitary and plasma. Horm Res 1999;51(suppl 1):2–6.
[PubMed]
20.
Zhan X, Giorgianni F, Desiderio DM: Proteomics analysis of growth hormone isoforms in the human pituitary. Proteomics 2005;5:1228–1241.
21.
Baxter RC, Brown AS, Turtle JR: Radioimmunoassay for somatomedin C: comparison with radioreceptor assay in patients with growth-hormone disorders, hypothyroidism, and renal failure. Clin Chem 1982;28:488–495.
22.
Lewis UJ, Sinha YN, Lewis GP: Structure and properties of members of the hGH family: a review. Endocr J 2000;47(suppl):S1–S8.
23.
Muller EE, Locatelli V, Cocchi D: Neuroendocrine control of growth hormone secretion. Physiol Rev 1999;79:511–607.
[PubMed]
24.
Bidlingmaier M, Wu Z, Strasburger CJ: Test method: GH. Baillieres Best Pract Res Clin Endocrinol Metab 2000;14:99–109.
25.
Wallace JD, Cuneo RC, Bidlingmaier M, Lundberg PA, Carlsson L, Boguszewski CL, Hay J, Boroujerdi M, Cittadini A, Dall R, Rosén T, Strasburger CJ: Changes in non-22-kilodalton (kDa) isoforms of growth hormone (GH) after administration of 22-kDa recombinant human GH in trained adult males. J Clin Endocrinol Metab 2001;86:1731–1737.
26.
Baxter RC: Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res 1994;42:140–144.
[PubMed]
27.
Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC: Growth hormone and bone. Endocr Rev 1998;19:55–79.
[PubMed]
28.
Seibel MJ: Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 2000;11(suppl 6): S18–S29.
29.
McHugh CM, Park RT, Sönksen PH, Holt RI: Challenges in detecting the abuse of growth hormone in sport. Clin Chem 2005;51:1587–1593.
30.
Dall R, Longobardi S, Ehrnborg C, Keay N, Rosén T, Jorgensen JO, Cuneo RC, Boroujerdi MA, Cittadini A, Napoli R, Christiansen JS, Bengtsson BA, Sacca L, Baxter RC, Basset EE, Sönksen PH: The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group. J Clin Endocrinol Metab 2000;85:4193–4200.
[PubMed]
31.
Powrie JK, Bassett EE, Rosén T, Jorgensen JO, Napoli R, Sacca L, Christiansen JS, Bengtsson BA, Sönksen PH: Detection of growth hormone abuse in sport. Growth Horm IGF Res 2007;17:220–226.
[PubMed]
32.
Wu Z, Bidlingmaier M, Dall R, Strasburger CJ: Detection of doping with human growth hormone. Lancet 1999;353:895.
[PubMed]
33.
Bidlingmaier M, Suhr J, Ernst A, Wu Z, Keller A, Strasburger CJ, Bergmann A: High-sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports. Clin Chem 2009;55:445–453.
34.
Hashimoto Y, Ikeda I, Ikeda M, Takahashi Y, Hosaka M, Uchida H, Kono N, Fukui H, Makino T, Honjo M: Construction of a specific and sensitive sandwich enzyme immunoassay for 20 kDa human growth hormone. J Immunol Methods 1998;221:77–85.
[PubMed]
35.
Tsushima T, Katoh Y, Miyachi Y, Chihara K, Teramoto A, Irie M, Hashimoto Y: Serum concentration of 20K human growth hormone (20K hGH) measured by a specific enzyme-linked immunosorbent assay. Study Group of 20K hGH. J Clin Endocrinol Metab 1999;84:317–322.
[PubMed]
36.
Nelson AE, Ueki M, Nguyen TV, Leung KC, Howe CJ, Trout GJ, Irie M, Baxter RC, Handelsman DJ, Kazlauskas R, Ho KK: The influence of demographic factors on the ratio of 20-kDa and 22-kDa GH isoforms and the utility of the ratio for detection of GH doping in sport. Growth Horm IGF Res 2006;16(suppl B):S3.
37.
Sönksen PH: Insulin, growth hormone and sport. J Endocrinol 2001;170:13–25.
[PubMed]
38.
Wallace JD, Cuneo RC, Baxter R, Orskov H, Keay N, Pentecost C, Dall R, Rosén T, Jorgensen JO, Cittadini A, Longobardi S, Sacca L, Christiansen JS, Bengtsson BA, Sönksen PH: Responses of the growth hormone (GH) and insulin-like growth factor axis to exercise, GH administration, and GH withdrawal in trained adult males: a potential test for GH abuse in sport. J Clin Endocrinol Metab 1999;84:3591–3601.
[PubMed]
39.
Wallace JD, Cuneo RC, Lundberg PA, Rosén T, Jorgensen JO, Longobardi S, Keay N, Sacca L, Christiansen JS, Bengtsson BA, Sönksen PH: Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration, and GH withdrawal in trained adult males. J Clin Endocrinol Metab 2000;85:124–133.
[PubMed]
40.
Longobardi S, Keay N, Ehrnborg C, Cittadini A, Rosén T, Dall R, Boroujerdi MA, Bassett EE, Healy ML, Pentecost C, Wallace JD, Powrie J, Jorgensen JO, Saccà L: Growth hormone (GH) effects on bone and collagen turnover in healthy adults and its potential as a marker of GH abuse in sports: a double blind, placebo-controlled study. The GH-2000 Study Group. J Clin Endocrinol Metab 2000;85:1505–1512.
41.
Kniess A, Ziegler E, Kratzsch J, Thieme D, Müller RK: Potential parameters for the detection of hGH doping. Anal Bioanal Chem 2003;376:696–700.
42.
Sartorio A, Agosti F, Marazzi N, Maffiuletti NA, Cella SG, Rigamonti AE, Guidetti L, Di Luigi L, Muller EE: Combined evaluation of resting IGF-I, N-terminal propeptide of type III procollagen (PIIINP) and C-terminal cross-linked telopeptide of type I collagen (ICTP) levels might be useful for detecting inappropriate GH administration in athletes: a preliminary report. Clin Endocrinol (Oxf) 2004;61:487–493.
43.
Ehrnborg C, Ohlsson C, Mohan S, Bengtsson BA, Rosén T: Increased serum concentration of IGFBP-4 and IGFBP-5 in healthy adults during one month’s treatment with supraphysiological doses of growth hormone. Growth Horm IGF Res 2007;17:234–241.
44.
Nelson AE, Meinhardt U, Hansen JL, Walker IH, Stone G, Howe CJ, Leung KC, Seibel MJ, Baxter RC, Handelsman DJ, Kazlauskas R, Ho KK: Pharmacodynamics of GH abuse biomarkers and the influence of gender and testosterone: a randomized double-blind placebo-controlled study in young recreational athletes. J Clin Endocrinol Metab 2008;93:2213–2222.
45.
Nelson AE, Howe CJ, Nguyen TV, Leung KC, Trout GJ, Seibel MJ, Baxter RC, Handelsman DJ, Kazlauskas R, Ho KK: Influence of demographic factors and sport type on growth hormone-responsive markers in elite athletes. J Clin Endocrinol Metab 2006;91:4424–4432.
46.
Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, Müller J, Skakkebaek NE: Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995;80:2534–2542.
[PubMed]
47.
Szulc P, Seeman E, Delmas PD: Biochemical measurements of bone turnover in children and adolescents. Osteoporos Int 2000;11:281–294.
[PubMed]
48.
Healy ML, Dall R, Gibney J, Bassett E, Ehrnborg C, Pentecost C, Rosén T, Cittadini A, Baxter RC, Sönksen PH: Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompetition setting. J Clin Endocrinol Metab 2005;90:641–649.
49.
Nguyen TV, Nelson AE, Howe CJ, Seibel MJ, Baxter RC, Handelsman DJ, Kazlauskas R, Ho KK: Within-subject variability and analytic imprecision of insulinlike growth factor axis and collagen markers: implications for clinical diagnosis and doping tests. Clin Chem 2008;54:1268–1276.
50.
Kurdy NM, Bowles S, Marsh DR, Davies A, France M: Serology of collagen types I and III in normal healing of tibial shaft fractures. J Orthop Trauma 1998;12:122–126.
51.
Stoffel K, Engler H, Kuster M, Riesen W: Changes in biochemical markers after lower limb fractures. Clin Chem 2007;53:131–134.
52.
Erotokritou-Mulligan I, Bassett EE, Bartlett C, Cowan D, McHugh C, Seah R, Curtis B, Wells V, Harrison K, Sönksen PH, Holt RI: The effect of sports injury on insulin-like growth factor-I and type 3 procollagen: implications for detection of growth hormone abuse in athletes. J Clin Endocrinol Metab 2008;93:2760–2763.
53.
Erotokritou-Mulligan I, Bassett EE, Kniess A, Sönksen PH, Holt RI: Validation of the growth hormone (GH)-dependent marker method of detecting GH abuse in sport through the use of independent data sets. Growth Horm IGF Res 2007;17:416–423.
54.
Nelson AE, Ho KK: A robust test for growth hormone doping – present status and future prospects. Asian J Androl 2008;10:416–425.
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.
